Tenglyn

Dosage

Children: Refer to specific product guidelines for dosage recommendations.

Adults: Refer to specific product guidelines for dosage recommendations.

Mechanism of action

The mechanism of action of hemipentahydrate varies depending on the specific compound it is associated with. Generally, compounds in a hemipentahydrate form are designed to dissolve in bodily fluids, allowing for the active ingredients to be released and exert their pharmacological effects. This can involve interactions with specific receptors or enzymes, leading to therapeutic outcomes.

Pharmacodynamics

Pharmacodynamics of hemipentahydrate compounds is reliant on the active drug's properties. Typically, these compounds may exhibit effects such as anti-inflammatory, analgesic, or antimicrobial actions, depending on the specific drug. The pharmacological effect is often dose-dependent, requiring careful consideration of the concentration of the active ingredient released from the hemipentahydrate form.

Pharmacokinetics

The pharmacokinetics of hemipentahydrate compounds include absorption, distribution, metabolism, and excretion (ADME). The hydration state can influence the solubility and, consequently, the absorption profile of the drug. Once absorbed, the distribution throughout the body will depend on the drug’s lipophilicity and protein binding capacity. Metabolism usually occurs in the liver, where the active compound may be converted into metabolites, and excretion typically happens via the kidneys.

Pregnancy

Safety in pregnancy has not been established. Consult healthcare provider before use.

Breast-feeding

Safety during breastfeeding has not been established. Consult healthcare provider before use.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Anxiety disorders
• Depression
• Neurological conditions

Dosage

Children: Refer to specific clinical guidelines or consult a healthcare provider for appropriate pediatric dosing.

Adults: Refer to specific clinical guidelines or consult a healthcare provider for appropriate dosing.

Mechanism of action

The precise mechanism of action for hemipentahydrobromide is not well-documented. However, compounds of this class often act on neurotransmitter receptors or ion channels, influencing synaptic transmission and neuronal excitability. This can lead to therapeutic effects in conditions like anxiety or depression, though further specific information is necessary for conclusive understanding.

Pharmacodynamics

Hemipentahydrobromide may exhibit dose-dependent effects on the central nervous system, potentially enhancing inhibitory neurotransmission through modulation of GABAergic pathways or antagonizing excitatory neurotransmitters. Its pharmacodynamic profile would depend on its affinity for various receptors and its effects on neuronal signaling pathways.

Pharmacokinetics

The pharmacokinetic properties of hemipentahydrobromide, such as absorption, distribution, metabolism, and excretion, are not well-established. Typically, drugs in this category may demonstrate variable absorption rates depending on formulation, while distribution may be influenced by lipophilicity. Metabolism could involve hepatic pathways, and elimination may be renal or through bile, requiring clinical monitoring for individual patient response.

Pregnancy

The safety of hemipentahydrobromide in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether hemipentahydrobromide is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Dehydration
• Electrolyte imbalance
• Heat-related illnesses
• Postoperative recovery
• Diarrhea and vomiting
• Chronic illnesses leading to fluid loss

Dosage

Children: Pediatric dosing should be guided by clinical guidelines and the severity of dehydration. For children experiencing mild to moderate dehydration, ORS is recommended, with the amount based on weight and age. For severe dehydration, intravenous fluid therapy is indicated, with specific protocols available in pediatric guidelines.

Adults: Dosage varies based on the degree of dehydration and the underlying clinical condition. For mild dehydration, oral rehydration solutions (ORS) are often sufficient, while severe cases may require intravenous fluids, with specific rates and types determined by clinical judgment.

Mechanism of action

Hydration works by replenishing lost fluids and electrolytes, restoring osmotic balance and cellular function. The primary components of hydration solutions, such as water, electrolytes (sodium, potassium, chloride), and sometimes glucose, promote proper cellular hydration and support metabolic processes.

Pharmacodynamics

The pharmacodynamics of hydration primarily involves the restoration of plasma volume and the maintenance of electrolyte homeostasis. Proper hydration enhances kidney function, improves cardiovascular stability, and supports normal physiological functions, such as thermoregulation and nutrient transport. It also aids in the recovery of tissues and organs affected by dehydration.

Pharmacokinetics

The pharmacokinetics of hydration solutions depend on the composition of the fluid administered. Oral hydration solutions are absorbed primarily in the gastrointestinal tract, with the rate of absorption influenced by the concentration of electrolytes and glucose. Intravenous fluids can distribute rapidly into the extracellular space, with effects seen almost immediately. The elimination of excess fluids occurs mainly through renal excretion.

Pregnancy

Hydration is essential during pregnancy, but fluid intake should be monitored to avoid excessive hydration, which can lead to complications.

Breast-feeding

Adequate hydration is important during breastfeeding, as it supports milk production. However, excessive fluid intake should be avoided.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Oral solutions
• Intravenous fluids
• Electrolyte solutions

Indications

• Respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease)
• Cough (e.g., as an antitussive)
• Anxiety and sleep disorders (when associated with specific formulations)

Dosage

Children: Refer to the BNF for Children for appropriate dosing information, as it is determined based on weight and age for the specific formulation.

Adults: Refer to the specific product monograph for dosing information, as it varies based on the drug formulation and indication.

Mechanism of action

Hydrobromides often act as competitive antagonists or agonists at specific receptor sites, depending on the drug involved. The exact mechanism can vary widely, but many hydrobromide-containing drugs modulate neurotransmitter activity, impacting various pathways in the body such as those involved in the central nervous system or respiratory function. The metabolic pathways include Phase I reactions primarily mediated by cytochrome P450 enzymes, which facilitate the functionalization and clearance of these compounds.

Pharmacodynamics

The pharmacodynamics of hydrobromide salts are largely determined by the specific drug they are associated with. Generally, hydrobromides may exhibit effects such as sedation, bronchodilation, or antitussive actions. The efficacy and adverse effects are influenced by the drug's receptor selectivity, affinity, and the pharmacological properties inherent to the parent compound.

Pharmacokinetics

Hydrobromides typically exhibit variable pharmacokinetic profiles depending on the specific drug formulation. They are generally absorbed rapidly following oral administration, with peak plasma concentrations occurring within a few hours. Metabolism primarily occurs in the liver through cytochrome P450 enzymes, particularly CYP2E1, among others. The elimination half-life varies but is often in the range of several hours, allowing for once or twice-daily dosing in many formulations. Excretion is usually via the kidneys, with metabolites being eliminated in urine.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed and the potential benefits justify the potential risks to the fetus.

Breast-feeding

Caution is advised; consider the importance of the drug to the mother against potential risks to the breastfeeding infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Type 2 diabetes mellitus
• Hyperglycemia in adults with type 2 diabetes

Dosage

Adults: The usual recommended dose of teneligliptin is 20 mg once daily, taken orally. In patients with renal impairment, dose adjustments may be required according to renal function.

Mechanism of action

Teneligliptin inhibits the enzyme DPP-4, which is responsible for the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, teneligliptin increases the levels of these incretins, leading to enhanced insulin secretion from the pancreatic beta cells and reduced glucagon secretion from the alpha cells. This mechanism helps to lower blood glucose levels in a glucose-dependent manner, thus minimizing the risk of hypoglycemia.

Pharmacodynamics

Teneligliptin exhibits a prolonged duration of action and has a favorable pharmacodynamic profile, leading to improved glycemic control in patients with type 2 diabetes. The increase in incretin hormones contributes to improved beta-cell function and insulin sensitivity. Additionally, teneligliptin may also have beneficial effects on body weight and lipid metabolism, making it a suitable option for overweight patients with type 2 diabetes.

Pharmacokinetics

Teneligliptin is absorbed rapidly following oral administration, with peak plasma concentrations typically reached within a few hours. It has a bioavailability of approximately 60-70%. The drug is extensively metabolized in the liver, primarily via the CYP3A4 pathway, with its elimination occurring mainly through renal excretion. The half-life of teneligliptin is around 10-12 hours, which allows for once-daily dosing. Factors such as renal impairment may necessitate dosage adjustments.

Contra-indications

• Hypersensitivity to teneligliptin or any of its components
• Severe renal impairment (eGFR < 15 mL/min)
• Diabetic ketoacidosis

Adverse effects

• Hypoglycemia
• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Headache
• Dizziness
• Pancreatitis
• Allergic reactions (rash, pruritus)

Interactions

• Caution with concomitant use of medications that affect glycemic control
• May interact with other antidiabetic agents, which can increase the risk of hypoglycemia
• Potential interaction with strong CYP3A4 inhibitors and inducers

Precautions

• Monitor renal function regularly
• Use with caution in patients with a history of pancreatitis
• Adjust dose in elderly patients or those with renal impairment

Pregnancy

There is limited data on the use of teneligliptin in pregnancy. It should only be used if the benefits outweigh the risks.

Breast-feeding

It is not known if teneligliptin is excreted in human milk. Caution should be exercised when administered to breastfeeding women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets of 20 mg